Resultados de búsqueda - Jochen Greiner

  • Mostrando 1 - 18 Resultados de 18
Limitar resultados
  1. 1
    Leukemia-Associated Antigens Are Critical for the Proliferation of Acute Myeloid Leukemia Cells

    Leukemia-Associated Antigens Are Critical for the Proliferation of Acute Myeloid Leukemia Cells por Jochen Greiner, Lars Bullinger, Barbara‐ann Guinn, Hartmut Döhner, Michael Schmitt

    Publicado 2008
    Enlace del recurso
    Revisão
    Agregar a favoritos
    Guardado en:
  2. 2
    Characterization of several leukemia‐associated antigens inducing humoral immune responses in acute and chronic myeloid leukemia

    Characterization of several leukemia‐associated antigens inducing humoral immune responses in acute and chronic myeloid leukemia por Jochen Greiner, Mark Ringhoffer, Masanori Taniguchi, Thomas Häuser, Anita Schmitt, Hartmut Döhner, Michael Schmitt

    Publicado 2003
    Enlace del recurso Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  3. 3
    Simultaneous expression of different immunogenic antigens in acute myeloid leukemia

    Simultaneous expression of different immunogenic antigens in acute myeloid leukemia por Jochen Greiner, Mark Ringhoffer, Oliver Simikopinko, Anita Szmaragowska, Sandra Huebsch, Ulrich Maurer, Lothar Bergmann, Michael Schmitt

    Publicado 2000
    Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  4. 4
    Immune responses against the mutated region of cytoplasmatic NPM1 might contribute to the favorable clinical outcome of AML patients with NPM1 mutations (NPM1mut)

    Immune responses against the mutated region of cytoplasmatic NPM1 might contribute to the favorable clinical outcome of AML patients with NPM1 mutations (NPM1mut) por Jochen Greiner, Vanessa Schneider, Michael Schmitt, Marlies Götz, Konstanze Döhner, Markus Wiesneth, Hartmut Döhner, Susanne Hofmann

    Publicado 2013
    Enlace del recurso Enlace del recurso
    Carta
    Agregar a favoritos
    Guardado en:
  5. 5
    Expression of RHAMM/CD168 and other tumor-associated antigens in patients with B-cell chronic lymphocytic leukemia

    Expression of RHAMM/CD168 and other tumor-associated antigens in patients with B-cell chronic lymphocytic leukemia por Krzysztof Giannopoulos, L Li, Agnieszka Bojarska−Junak, Jacek Roliński, Anna Dmoszyńska, Iwona Hus, Jochen Greiner, C Renner, H. Döhner, Michael Schmitt

    Publicado 2006
    Enlace del recurso Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  6. 6
    Mutated regions of nucleophosmin 1 elicit both CD4+ and CD8+ T-cell responses in patients with acute myeloid leukemia

    Mutated regions of nucleophosmin 1 elicit both CD4+ and CD8+ T-cell responses in patients with acute myeloid leukemia por Jochen Greiner, Yoko Ono, Susanne Hofmann, Anita Schmitt, Elmar Mehring, Marlies Götz, Philippe Guillaume, Konstanze Döhner, Joannis Mytilineos, Hartmut Döhner, Michael Schmitt

    Publicado 2012
    Enlace del recurso Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  7. 7
    Identification and characterization of epitopes of the receptor for hyaluronic acid–mediated motility (RHAMM/CD168) recognized by CD8+ T cells of HLA-A2–positive patients with acute myeloid leukemia

    Identification and characterization of epitopes of the receptor for hyaluronic acid–mediated motility (RHAMM/CD168) recognized by CD8+ T cells of HLA-A2–positive patients with acut... por Jochen Greiner, Li Li, Mark Ringhoffer, Thomas F.E. Barth, Krzysztof Giannopoulos, Phillipe Guillaume, Gerd Ritter, Markus Wiesneth, Hartmut Döhner, Michael Schmitt

    Publicado 2005
    Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  8. 8
    Immunotherapy for patients with acute myeloid leukemia using autologous dendritic cells generated from leukemic blasts

    Immunotherapy for patients with acute myeloid leukemia using autologous dendritic cells generated from leukemic blasts por Li Li, Krzysztof Giannopoulos, Peter Reinhardt, Jacek Tabarkiewicz, Anita Schmitt, Jochen Greiner, Jacek Roliński, Iwona Hus, Anna Dmoszyńska, Markus Wiesneth, Michael Schmitt

    Publicado 2006
    Enlace del recurso Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  9. 9
    Dasatinib exerts an immunosuppressive effect on CD8+ T cells specific for viral and leukemia antigens

    Dasatinib exerts an immunosuppressive effect on CD8+ T cells specific for viral and leukemia antigens por Fei Fei, Yingzhe Yu, Anita Schmitt, Markus Rojewski, Baoan Chen, Jochen Greiner, Marlies Götz, Philippe Guillaume, Hartmut Döhner, Donald Bunjes, Michael Schmitt

    Publicado 2008
    Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  10. 10
    Receptor for hyaluronan acid–mediated motility (RHAMM) is a new immunogenic leukemia-associated antigen in acute and chronic myeloid leukemia

    Receptor for hyaluronan acid–mediated motility (RHAMM) is a new immunogenic leukemia-associated antigen in acute and chronic myeloid leukemia por Jochen Greiner, Mark Ringhoffer, Masanori Taniguchi, Anita Schmitt, Dieter Kirchner, Gertraud Krähn, V. Heilmann, Jürgen E. Gschwend, Lothar Bergmann, Hartmut Döhner, Michael Schmitt

    Publicado 2002
    Enlace del recurso Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  11. 11
    Expression of tumor-associated antigens in acute myeloid leukemia: implications for specific immunotherapeutic approaches

    Expression of tumor-associated antigens in acute myeloid leukemia: implications for specific immunotherapeutic approaches por Jochen Greiner, Michael Schmitt, Li Li, Krzysztof Giannopoulos, Katrin Bosch, Anita Schmitt, Konstanze Döhner, Richard F. Schlenk, Jonathan R. Pollack, Hartmut Döhner, Lars Bullinger

    Publicado 2006
    Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  12. 12
    High-dose RHAMM-R3 peptide vaccination for patients with acute myeloid leukemia, myelodysplastic syndrome and multiple myeloma

    High-dose RHAMM-R3 peptide vaccination for patients with acute myeloid leukemia, myelodysplastic syndrome and multiple myeloma por Jochen Greiner, Anita Schmitt, Krzysztof Giannopoulos, Markus Rojewski, Mario E. Götz, I. Funk, Mark Ringhoffer, Donald Bunjes, Susanne Hofmann, Gerd Ritter, Hartmut Döhner, Michael Schmitt

    Publicado 2010
    Enlace del recurso Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  13. 13
    RHAMM (CD168) Is Overexpressed at the Protein Level and May Constitute an Immunogenic Antigen in Advanced Prostate Cancer Disease

    RHAMM (CD168) Is Overexpressed at the Protein Level and May Constitute an Immunogenic Antigen in Advanced Prostate Cancer Disease por Kilian M. Gust, Matthias D. Hofer, Sven Perner, Robert Kim, Arul M. Chinnaiyan, Sooryanarayana Varambally, Peter Möller, L. Rinnab, Mark A. Rubin, Jochen Greiner, Michael Schmitt, Rainer Kuefer, Mark Ringhoffer

    Publicado 2009
    Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  14. 14
    Lenalidomide maintenance after allogeneic HSCT seems to trigger acute graft-versus-host disease in patients with high-risk myelodysplastic syndromes or acute myeloid leukemia and del(5q): results of the LENAMAINT trial

    Lenalidomide maintenance after allogeneic HSCT seems to trigger acute graft-versus-host disease in patients with high-risk myelodysplastic syndromes or acute myeloid leukemia and d... por Katja Sockel, Martin Bornhaeuser, Eva M. Weissinger, Rudolf Trenschel, Martin Wermke, Christian Unzicker, Guido Kobbe, Jürgen Finke, Ulrich Germing, Brigitte Mohr, Jochen Greiner, Dietrich W. Beelen, Christian Thiede, Gerhard Ehninger, Uwe Platzbecker

    Publicado 2012
    Enlace del recurso Enlace del recurso
    Carta
    Agregar a favoritos
    Guardado en:
  15. 15
    Nilotinib hampers the proliferation and function of CD8<sup>+</sup> T lymphocytes through inhibition of T cell receptor signalling

    Nilotinib hampers the proliferation and function of CD8<sup>+</sup> T lymphocytes through inhibition of T cell receptor signalling por J. Chen, Anita Schmitt, B. Chen, Markus Rojewski, V. RuBeler, F. Fei, Yingzhe Yu, Xiaqing Yu, Mark Ringhoffer, S. von Harsdorf, Jochen Greiner, M. Gbtzz, Philippe Guillaume, H. Dbhner, Donald Bunjes, Michael Schmitt

    Publicado 2008
    Enlace del recurso Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  16. 16
    RHAMM-R3 peptide vaccination in patients with acute myeloid leukemia, myelodysplastic syndrome, and multiple myeloma elicits immunologic and clinical responses

    RHAMM-R3 peptide vaccination in patients with acute myeloid leukemia, myelodysplastic syndrome, and multiple myeloma elicits immunologic and clinical responses por Michael Schmitt, Anita Schmitt, Markus Rojewski, Jinfei Chen, Krzysztof Giannopoulos, Fei Fei, Yingzhe Yu, Marlies Götz, Marta Heyduk, Gerd Ritter, Daniel E. Speiser, Sacha Gnjatic, Philippe Guillaume, Mark Ringhoffer, Richard F. Schlenk, Peter Liebisch, Donald Bunjes, Hiroshi Shiku, Hartmut Döhner, Jochen Greiner

    Publicado 2007
    Enlace del recurso Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  17. 17
    Clofarabine Plus Cytarabine Compared With Cytarabine Alone in Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia: Results From the CLASSIC I Trial

    Clofarabine Plus Cytarabine Compared With Cytarabine Alone in Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia: Results From the CLASSIC I Trial por Stefan Faderl, Meir Wetzler, David A. Rizzieri, Gary J. Schiller, Madan Jagasia, Robert K. Stuart, Siddhartha Ganguly, David Avigan, Michael Craig, Robert H. Collins, Michael B. Maris, Tibor Kovacsovics, Stuart L. Goldberg, Karen Seiter, Parameswaran Hari, Jochen Greiner, Norbert Vey, Christian Récher, Farhad Ravandi, Eunice S. Wang, Michael J. Vasconcelles, Dirk Huebner, Hagop M. Kantarjian

    Publicado 2012
    Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  18. 18
    Early, very high-titre convalescent plasma therapy in clinically vulnerable individuals with mild COVID-19: an international, randomised, open-label trial

    Early, very high-titre convalescent plasma therapy in clinically vulnerable individuals with mild COVID-19: an international, randomised, open-label trial por Simone Hoffmann, Eva Schrezenmeier, Maxime Desmarets, Fabian Halleck, Antoine Dürrbach, Lynn Peters, Anna Tremmel, Alina Seidel, Marita Führer, Friederike Bachmann, Jens Schrezenmeier, Jochen Greiner, Sixten Körper, Henrike Hofmann, Carolin Ludwig, Christiane Vieweg, Bernd Jahrsdörfer, Klemens Budde, Michael Schmidt, Jan Münch, Nizar Joher, Étienne Daguindau, Beate Grüner, Gaëlle Brunotte, Charline Vauchy, Erhard Seifried, Daniel Bradshaw, Lise J Estcourt, David Roberts, Éric Toussirot, Bart Rijnders, Pierre Tiberghien, Hubert Schrezenmeier

    Publicado 2025
    Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:

Herramientas de búsqueda: